Senem Karabulut

1.3k total citations
96 papers, 1.0k citations indexed

About

Senem Karabulut is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Senem Karabulut has authored 96 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 30 papers in Molecular Biology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Senem Karabulut's work include Gastric Cancer Management and Outcomes (11 papers), Cell Adhesion Molecules Research (10 papers) and Cancer Cells and Metastasis (9 papers). Senem Karabulut is often cited by papers focused on Gastric Cancer Management and Outcomes (11 papers), Cell Adhesion Molecules Research (10 papers) and Cancer Cells and Metastasis (9 papers). Senem Karabulut collaborates with scholars based in Türkiye, Antigua and Barbuda and Cambodia. Senem Karabulut's co-authors include Derya Duranyıldız, Rümeysa Çiftçi, Faruk Taş, Leyla Kılıç, Murat Serilmez, Faruk Taş, Didem Taştekin, Mehmet Karabulut, Çiğdem Usul Afşar and Elif Bilgin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Senem Karabulut

87 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Senem Karabulut Türkiye 18 483 310 243 185 142 96 1.0k
Seongyeol Park South Korea 17 430 0.9× 322 1.0× 209 0.9× 190 1.0× 239 1.7× 33 971
Koichi Okamoto Japan 20 360 0.7× 342 1.1× 170 0.7× 156 0.8× 129 0.9× 86 927
Kyu Yeoun Won South Korea 19 286 0.6× 433 1.4× 226 0.9× 257 1.4× 165 1.2× 74 1.0k
Jędrzej Grzegrzółka Poland 18 427 0.9× 466 1.5× 169 0.7× 259 1.4× 140 1.0× 76 1.1k
Kenji Hashimoto Japan 19 568 1.2× 289 0.9× 248 1.0× 123 0.7× 175 1.2× 54 1.1k
Tanja Langsenlehner Austria 19 595 1.2× 325 1.0× 322 1.3× 363 2.0× 98 0.7× 56 1.2k
Masayuki Tanahashi Japan 19 521 1.1× 517 1.7× 459 1.9× 229 1.2× 169 1.2× 97 1.3k
Vito Longo Italy 23 372 0.8× 467 1.5× 130 0.5× 151 0.8× 168 1.2× 38 1.1k
Zhenhai Lu China 18 554 1.1× 398 1.3× 197 0.8× 273 1.5× 125 0.9× 55 1.1k

Countries citing papers authored by Senem Karabulut

Since Specialization
Citations

This map shows the geographic impact of Senem Karabulut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Senem Karabulut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Senem Karabulut more than expected).

Fields of papers citing papers by Senem Karabulut

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Senem Karabulut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Senem Karabulut. The network helps show where Senem Karabulut may publish in the future.

Co-authorship network of co-authors of Senem Karabulut

This figure shows the co-authorship network connecting the top 25 collaborators of Senem Karabulut. A scholar is included among the top collaborators of Senem Karabulut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Senem Karabulut. Senem Karabulut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Karabulut, Senem, Hilal Oğuz, Didem Taştekin, et al.. (2024). Investigation of the potential of miRNA candidates as non-invasive biomarkers for the diagnosis and follow-up of colorectal cancer. Pathology - Research and Practice. 254. 155094–155094. 4 indexed citations
2.
Karabulut, Senem, et al.. (2022). Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer. Journal of College of Physicians And Surgeons Pakistan. 32(8). 1014–1019. 2 indexed citations
3.
Özkan, Zeynep Gözde, Duygu Has Şimşek, Serkan Kuyumcu, et al.. (2021). Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up. Annals of Nuclear Medicine. 36(1). 52–60. 1 indexed citations
4.
Karabulut, Senem, et al.. (2021). METASTATİK KOLON KANSERİ TEDAVİSİNDEKİ YENİLİKLER. SHILAP Revista de lepidopterología. 84(3). 425–429.
5.
Arslan, Esra, et al.. (2020). Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT. Revista da Associação Médica Brasileira. 66(5). 673–679. 2 indexed citations
6.
Taş, Faruk, Senem Karabulut, Kayhan Ertürk, & Derya Duranyıldız. (2018). Clinical significance of serum leptin level in patients with gastric cancer. European Cytokine Network. 29(2). 52–58. 9 indexed citations
7.
Korkmaz, Levent, Hasan Şenol Çoşkun, Faysal Dane, et al.. (2018). Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study. Surgical Oncology. 27(3). 485–489. 6 indexed citations
8.
Karabulut, Senem, Çiğdem Usul Afşar, Mehmet Karabulut, et al.. (2017). Clinical significance of serum interleukin-17 levels in colorectal cancer patients.. PubMed. 21(5). 1137–1145. 7 indexed citations
9.
Karabulut, Senem, Mehmet Karabulut, Çiğdem Usul Afşar, et al.. (2016). PANKREAS ADENOKARSİNOMLU HASTALARDA SERUM TRANSFORME EDİCİ BÜYÜME FAKTÖR BETA 1 (TGF-Β1) DÜZEYLERİ. Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi. 79(1). 9–9. 1 indexed citations
10.
Taş, Faruk, Elif Bilgin, Senem Karabulut, & Derya Duranyıldız. (2016). Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients. Molecular and Clinical Oncology. 5(1). 195–200. 4 indexed citations
11.
Taş, Faruk, Senem Karabulut, Didem Taştekin, & Derya Duranyıldız. (2016). Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients. Biomedical Reports. 4(4). 489–492. 3 indexed citations
12.
Taş, Faruk, Elif Bilgin, Senem Karabulut, Kayhan Ertürk, & Derya Duranyıldız. (2016). Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma. PubMed. 5. 166–169. 2 indexed citations
13.
Karabulut, Mehmet, Halil Alış, Çiğdem Usul Afşar, et al.. (2015). Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer. Biomedicine & Pharmacotherapy. 73. 140–146. 8 indexed citations
14.
Taş, Faruk, Senem Karabulut, İbrahim Yıldız, & Derya Duranyıldız. (2014). Clinical significance of serum M30 and M65 levels in patients with breast cancer. Biomedicine & Pharmacotherapy. 68(8). 1135–1140. 10 indexed citations
15.
Çiftçi, Rümeysa, Faruk Taş, Senem Karabulut, et al.. (2014). High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer. Tumor Biology. 35(7). 6941–6948. 19 indexed citations
16.
17.
Taştekin, Didem, et al.. (2014). Clinical significance of serum tenascin-C levels in breast cancer. Tumor Biology. 35(7). 6619–6625. 16 indexed citations
18.
Karabulut, Senem, et al.. (2014). The Behavior of Turkish Cancer Patients in Fasting During the Holy Month of Ramadan. Japanese Journal of Clinical Oncology. 44(8). 705–710. 8 indexed citations
19.
Aydıner, Adnan, Rümeysa Çiftçi, Senem Karabulut, & Leyla Kılıç. (2013). Does Beta-blocker Therapy Improve the Survival of Patients with Metastatic Non-small Cell Lung Cancer?. Asian Pacific Journal of Cancer Prevention. 14(10). 6109–6114. 42 indexed citations
20.
Aykan, Nuri Faruk, İbrahim Yıldız, Fatma Şen, et al.. (2013). Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. Medical Oncology. 30(3). 679–679. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seongyeol Park Breakdown of academic impact, for papers by Koichi Okamoto Breakdown of academic impact, for papers by Kyu Yeoun Won Breakdown of academic impact, for papers by Jędrzej Grzegrzółka Breakdown of academic impact, for papers by Kenji Hashimoto Breakdown of academic impact, for papers by Tanja Langsenlehner Breakdown of academic impact, for papers by Masayuki Tanahashi Breakdown of academic impact, for papers by Vito Longo Breakdown of academic impact, for papers by Zhenhai Lu
Rankless by CCL
2026